Algen Biotechnologies utilizes a proprietary CRISPR gene-modulation system and advanced AI models to decode complex gene networks and identify disease-driving RNA signaling pathways. This approach accelerates therapeutic drug discovery by providing high-confidence insights into the biological mechanisms underlying various diseases.
Funding
$9.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Identifying disease-driving RNA signaling pathways is challenging due to the complexity of gene networks and the difficulty of decoding the biological mechanisms underlying various diseases. Traditional therapeutic drug discovery methods often lack the speed and precision needed to effectively target these complex pathways.
Solution
Algen Biotechnologies leverages a proprietary, next-generation CRISPR gene-modulation system (AlgenCRISPR) and advanced AI models (AlgenBrain) to accelerate therapeutic drug discovery. AlgenCRISPR offers robust, fine-tuned, and precise gene modulation to deconvolute complex biology. The AlgenBrain platform industrializes single-cell, combinatorial gene modulation, driving towards impactful human-centric therapeutic endpoints. Algen's deep learning models are built on billions of real-time, dynamic gene expression changes that occur throughout disease progression, illuminating disease-driving RNA signaling pathways and extracting insights for drug discovery.
Target Audience
The primary audience includes pharmaceutical companies and research institutions focused on therapeutic drug discovery.
Features
- AlgenCRISPR: A proprietary, next-generation CRISPR system for robust and precise gene modulation.
- AlgenBrain: An AI foundation model to predict RNA signaling networks.
- Single-cell, combinatorial gene modulation to drive towards human-centric therapeutic endpoints.
- Deep learning models built on billions of real-time, dynamic gene expression changes.
- Identification of disease-driving RNA signaling pathways.